Annual Report 2021

NOTESTOTHE CONSOLIDATED FINANCIAL STATEMENTS For the year ended 31 December 2021 86 The United Laboratories International Holdings Limited Annual Report 2021 5. REVENUE AND SEGMENT INFORMATION (Continued) Segment information (Continued) (a) Segment revenue and results (Continued) Year ended 31 December 2020 Intermediate Bulk Finished Segment products medicine products total Elimination Consolidated RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 RMB’000 REVENUE External sales 1,429,690 3,620,720 3,722,078 8,772,488 – 8,772,488 Inter-segment sales 1,397,230 592,085 – 1,989,315 (1,989,315) – Segment revenue 2,826,920 4,212,805 3,722,078 10,761,803 (1,989,315) 8,772,488 RESULT Segment profit 258,072 212,015 886,608 1,356,695 Unallocated other income 193,232 Unallocated corporate expenses (110,696) Unallocated other gains and losses, net 8,372 Loss on fair value change of embedded derivative components of convertible bonds (314,614) Impairment losses under expected credit loss model, net of reversal (69,382) Finance costs (181,273) Profit before taxation 882,334